Clarithromycin related compound C

Clarithromycin related compound C

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Clarithromycin related compound C
Category Others
Catalog number BBF-04427
CAS 103450-87-9
Molecular Weight 762.97
Molecular Formula C38H70N2O13
Purity >95% by HPLC

Online Inquiry

Description

An impurity found in the macrolide antibiotic, Clarithromycin.

Specification

Synonyms 6-O-Methylerythromycin 9-Oxime; Clarithromycin Impurity C
Storage Store at -20°C under inert atmosphere
IUPAC Name (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-10-hydroxyimino-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
Canonical SMILES CCC1C(C(C(C(=NO)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
InChI InChI=1S/C38H70N2O13/c1-15-26-38(10,45)31(42)21(4)28(39-46)19(2)17-37(9,48-14)33(53-35-29(41)25(40(11)12)16-20(3)49-35)22(5)30(23(6)34(44)51-26)52-27-18-36(8,47-13)32(43)24(7)50-27/h19-27,29-33,35,41-43,45-46H,15-18H2,1-14H3/b39-28+/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
InChI Key MWBJRTBANFUBOX-SQYJNGITSA-N

Properties

Appearance White to Off-white Solid
Boiling Point 827.7±65.0°C (Predicted)
Melting Point 169-171°C
Density 1.26±0.1 g/cm3 (Predicted)
Solubility Slightly soluble in Chloroform, Methanol

Reference Reading

1.Isolation and identification of a novel impurity of erythromycin A 9-oxime desosaminehydrazinium salt.
Zhou CC, Huang X, Ford KL, Hollis LS. J Antibiot (Tokyo). 2005 Aug;58(8):539-44.
In the manufacturing process for Biaxin (clarithromycin), erythromycin-A oxime, an intermediate, is obtained in high yield, when erythromycin-A is treated with hydroxylamine/isopropyl alcohol in the presence of acetic acid. An unusual impurity, the desosamine hydrazinium salt, is generated in this step of the synthetic pathway, and has been isolated and characterized by using one and two-dimensional NMR spectroscopy in conjunction with MS and EDS.
2.Design, synthesis and antibacterial activity of a novel alkylide: 3-O-(3-aryl-propenyl)clarithromycin derivatives.
Liang JH1, Wang YY, Zhu DY, Dong LJ, An MM, Wang R, Yao GW. J Antibiot (Tokyo). 2009 Nov;62(11):605-11. doi: 10.1038/ja.2009.89. Epub 2009 Aug 28.
A series of novel 3-O-(3-aryl-propenyl)clarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activities. Regioselective allylation at 3-OH was efficiently achieved in the presence of 9-oxime ether, compared with 9-keto. Most of the side chains were identified as the 3-O-(3-aryl-Z-prop-1-enyl) group, not the expected 3-O-(3-aryl-E-prop-2-enyl) group. Some derivatives of this series showed improved activities against erythromycin-resistant Staphylococcus aureus and Staphylococcus pneumoniae compared with the reference compound, clarithromycin, but weaker activities against susceptible strains.
3.[Research and development of clarithromycin].
Omura S1, Morimoto S, Nagate T, Adachi T, Kohno Y. Yakugaku Zasshi. 1992 Sep;112(9):593-614.
A series of O-alkylated derivatives of erythromycin (EM) has been prepared and their biological properties were evaluated. Among them, clarithromycin (CAM, 6-O-methylerythromycin) exhibits most potent in vitro and in vivo antibacterial activities, higher acid-stability than EM and favorable pharmacokinetic properties as an antibiotic. CAM was originally synthesized via methylation of 2'-O,3'-N-bis(benzyl-oxycarbonyl)-N-demethylerythromycin in low yield, because of the less selectivity of 6-O-methylation. The selective 6-O-methylation was achieved using the erythromycin 9-oxime derivative as a key intermediate. By the further investigation on the protective groups of 9-oxime and desosamine moiety, the production process of CAM on an industrial scale has been established via methylation of 2',4''-O-bis(trimethylsilyl)erythromycin 9-[O-(1-isopropoxycyclohexyl)oxime] in more than 45% overall yield. CAM has the same antibacterial spectra as EM and is active against aerobic Gram-positive bacteria, some Gram-negative bacteria, anaerobic bacteria, Mycoplasma and Chlamydia.
4.[Analysis of the key intermediates for the regioselectivity control in the methylation of the manufacture of clarithromycin by reversed-phase high performance liquid chromatography].
Liang J1, Yao G, Zheng S. Se Pu. 2004 May;22(3):237-40.
2',4''-O-Bis(trimethylsilyl)erythromycin A-9-O-(1-isopropoxycyclohexyl)oxime (2',4''-TMS-EMIPCH) and 2',4''-O-bis(trimethylsilyl)-6-O-methylerythromycin A-9-O-(1-isopropoxycyclohexyl)oxime (2',4"-TMS-IPCH) are the key intermediates for manufacturing clarithromycin. A qualitative and quantitative method for baseline separation of E- and Z-isomers and related process substances has been established. A DIKMA-Inertsil ODS-3 column (150 mm x 4.6 mm i.d., 5 microm) was used. The column temperature was maintained at 40 degrees C. The mobile phase was CH3CN-H2O (95:5, v/v). The flow rate was 1.5 mL/min and the detection wavelength was UV 205 nm. Good linearities for E-2',4''-TMS-EMIPCH and E-2',4''-TMS-IPCH were obtained in the ranges of 6-60 microg (r = 0.9994) and 6-72 microg (r = 0.9998), respectively. The method described has also been demonstrated to work equally well on other 2',4''-O-bis(trimethylsilyl)erythromycin 9-oxime hydroxyl derivatives, which provided the criterion for optimizing the protective groups at 9-oxime hydroxyl position and the study of regioselectivity of methylation at the 6-OH position.

Recommended Products

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code
cartIcon
Inquiry Basket